SALT LAKE CITY - Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical stage company specializing in drug discovery through technological innovation, announced its intention to conduct a public offering of $200 million worth of its Class A common stock. The company, which is based in Salt Lake City, also plans to give underwriters a 30-day option to purchase an additional 15% of the shares being offered.
The offering's completion is subject to market conditions, and there is no guarantee of its exact size or terms. Investment banks Goldman Sachs (NYSE:GS) & Co. LLC and J.P. Morgan are leading the offering as book-running managers, with Allen & Company LLC also managing the books.
Recursion's offering is made in accordance with a registration statement that was automatically effective upon its filing with the U.S. Securities and Exchange Commission (SEC) on May 10, 2022. Details about the offering will be available through a preliminary prospectus supplement and accompanying prospectus, which can be obtained from the SEC's website or directly from the managing banks.
The company emphasizes that this announcement is not an offer to sell or a solicitation to buy these securities in any jurisdiction where the offer or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
Recursion is known for its Recursion Operating System (OS), which combines machine learning, massive experimental and computational scale, and a proprietary dataset to enhance drug discovery. The company operates offices in Salt Lake City, Toronto, Montreal, the San Francisco Bay Area, and London.
InvestingPro Insights
As Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) prepares for its public offering, a glance at the company's financial health through InvestingPro data reveals a market capitalization of approximately $2.09 billion. Despite a challenging environment, the company has shown a quarterly revenue growth of 13.68% in Q1 2023. However, this growth is juxtaposed with a negative gross profit margin of -34.5% over the last twelve months, indicating that costs have outweighed revenue during this period.
InvestingPro Tips suggest that Recursion holds more cash than debt, which is a positive sign for potential investors concerned about the company's liquidity. Additionally, the company's liquid assets exceed its short-term obligations, providing a buffer for operational needs. These factors are crucial for a clinical-stage company that is not yet profitable and is quickly burning through cash.
It's important to note that analysts do not expect Recursion to be profitable this year, and the company does not pay dividends, which may influence investment strategies focused on income or near-term profitability. With a P/E ratio of -5.43, the company is trading at a high revenue valuation multiple, which can be a sign of market optimism about its future growth prospects.
For those interested in a deeper analysis, InvestingPro offers additional tips on Recursion Pharmaceuticals, providing a comprehensive look at the financial metrics and expert insights. By using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.